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A c c e p t e d M a n u s c r i p t 2 Cisplatin is commonly used in ovarian cancer treatment by inducing apoptosis in cancer cells as a result of lethal DNA damage. However, the intrinsic and acquired resistance to cisplatin in cancer cells remains a big challenge for improving overall survival. The cytoprotective functions of autophagy in cancer cells have been suggested as a potential mechanism for chemoresistance. Here, we reported MIR152 as a new autophagyregulating miRNA that plays a role in cisplatin-resistance. We showed that MIR152 We also identified that ATG14 is a functional target of MIR152 in regulating autophagy inhibition. Furthermore, we found that EGR1 (early growth response 1) regulated the MIR152 gene at the transcriptional level. Ectopic expression of EGR1 enhanced efficacy of chemotherapy in A2780/CP70 cells. More importantly, these findings were relevant to clinical cases. Both EGR1 and MIR152 expression levels were significantly lower in ovarian cancer tissues with high levels of ERCC1 (excision repair cross-complementation group 1), a marker for cisplatin-resistance. Collectively, these data provide insights into novel mechanisms for acquired cisplatin-resistance. Activation of EGR1 and MIR152 may be a useful therapeutic strategy to overcome cisplatin-resistance by preventing cytoprotective autophagy in ovarian cancer.
A c c e p t e d M a n u s c r i p t
Introduction
Epithelial ovarian cancers (EOC) remain the most lethal gynecological malignancy due to the heterogeneous nature of the disease and late diagnosis. The standard therapy includes maximum surgical debulking of tumor mass followed by platinum/taxane chemotherapy in which initial response rates may reach 80% high. 1 However, the recurrence rate exceeds 75%, and the success of subsequent chemotherapy is limited because of the progressive development of drug resistance. [2] Moreover, recurrent ovarian tumors are more aggressive and likely to metastasize to secondary tissues in patients. It is of importance to understand new mechanism(s) of chemoresistance and to develop new strategies for ovarian cancer treatments.
The potential mechanisms underlying platinum-based chemotherapy involve the nuclear excision repair (NER) system, acquired genetic mutation, and oncogenic pathways activated by cisplatin-induced DNA lesions. 3 Recent findings support the theory that the cyto-protective functions of autophagy in cancer cells may serve as a potential mechanism for therapeutic resistance. Autophagy is a lysosome degradation response to cellular stressors whereby cellular proteins, organelles, and cytoplasm are engulfed, digested, and recycled to maintain cellular homeostasis. 4 Except for its role in physiological process, the implication of autophagy in cancer is complicated and contextdependent. Researchers generally agree that autophagy protects cells from genotoxic stress that can lead to oncogenic transformation by killing cells to prevent tumor initiation. Once tumors are established, autophagy can be used as a survival strategy by cancer cells to overcome the stresses caused by radiation, chemotherapy, or other A c c e p t e d M a n u s c r i p t 4 treatments. 5 However, how tumor cells utilize autophagy to prevent radiation-or chemotherapy-mediated cell death remains elusive.
MiRNAs are small, noncoding RNA molecules, which function by modulating the expression levels of target genes through sequence complementarity between miRNAs and their target mRNAs, thus leads to either protein translation inhibition or mRNA degradation. 6 Deregulations of miRNA expression profiles have been associated with cancer development and progression, and have been well documented as one of hallmarks of cancer. 7 With regards to autophagy, the contribution of post-transcriptional control of autophagy mediated by miRNAs in cancer emerged just recently. It has been
shown that miRNAs play roles in regulating autophagy by modulating expression of key autophagy-related proteins. 8 As most cancer treatments induce autophagy in drugresistant cancer cells, we hereby utilized 2 cisplatin-resistant ovarian cancer cell lines A2780/CP70, SKOV3/DDP, and their parental A2780 and SKOV3 cells as well as human ovarian cancer tissues to identify: 1) roles of miRNA(s) in cisplatin-induced autophagy associated with the drug resistance; 2) functional target genes of the miRNA(s) that conveys drug resistance; 3) the relevant signaling pathway for regulating the process; and 4) the clinical implication of these findings.
Results

Cisplatin induces autophagic flux in cisplatin-resistant ovarian cancer cells
Detection of MAP1LC3/LC3 (microtubule-associated protein 1 light chain 3), a mammalian ortholog of yeast Atg8, is a common way to monitor autophagy. During autophagy induction, the nonlipidated form of LC3 (LC3-I) is conjugated with A c c e p t e d M a n u s c r i p t 5 phosphatidylethanolamine (PE), then converted into the lipidated form of LC3 (LC3-II), which is associated with autophagosome biogenesis. 9 As LC3-II is rapidly degraded by lysosomal turnover during autophagy, we treated cells with cisplatin in the presence or absence of the lysosome inhibitor chloroquine (CQ). The autophagic flux can be reflected by the fold change in LC3-II levels with or without chloroquine. 10, 11 We found that the fold change in LC3-II levels in cisplatin-resistant A2780/CP70 cells after lysosome inhibition via chloroquine was remarkably upregulated in response to cisplatin treatment, suggesting autophagy induction ( (Fig. 1B) . In addition to LC3-II, the receptor SQSTM1 has also been used as a marker of autophagy induction. The SQSTM1 protein links LC3 and ubiquitinated substrates, 12 which are degraded during autophagic flux. As expected, SQSTM1 levels were decreased with cisplatin treatment in A2780/CP70 cells (Fig. 1C) . It is known that the MTOR complex is a negative regulator of autophagy.
M a n u s c r i p t 6 phosphorylation of RPS6KB1/p70S6K1, indicating that cisplatin-induced autophagy in cisplatin-resistant cells was MTOR-independent (Fig. 1C) .
A MIR152 mimic sensitizes ovarian cancer cells to cisplatin-induced cell death
Recent studies suggest that miRNAs may regulate autophagic activity by directly targeting autophagy-related proteins or pathways. 8 We screened a number of miRNAs, which are differentially expressed in ovarian cancer tissues relative to normal tissues based on literature reviews (data not shown). We found MIR152 expression levels were 
ATG14 is a direct target of MIR152
To reveal the mechanism of autophagy inhibition by MIR152, we searched autophagyrelated genes using a bioinformatic database using Targetscan, and found that ATG14 is predicted to bind with 3'UTR regions of ATG14 mRNA. We constructed the 3' UTR reporters of ATG14 containing the putative MIR152 binding sites and corresponding mutant constructs downstream of the luciferase reporters. Then we cotransfected 293T
cells and A2780 cells with reporter constructs, the MIR152 mimic or MIR-C, and a b-gal plasmid, then performed the luciferase activity assay 48 h after transfection. As shown in Then we assessed the action of ATG14 on cisplatin resistance. ATG14 was silenced by siRNA in A2780/CP70 cells treated with cisplatin. Knockdown of ATG14 resulted in 31%
cisplatin-induced apoptosis compared with 18% in scrambled siRNA control cells (Fig.   5C ). To further confirm the finding, we also tested the effect of ATG7 on cisplatin resistance. ATG7 is one of well-established autophagy related proteins, which is critical in autophagosomal biogenesis. It was reported that ATG7 deficiency promoted cisplatininduced apoptotic death in human esophageal squamous cell carcinoma cells. 16 As expected, we observed an increased cisplatin-induced apoptosis and necrosis in ATG7 knockdown cells. These results indicate that ATG14 is capable of sensitizing cisplatinresistant ovarian cancer cells to chemotherapy. A c c e p t e d M a n u s c r i p t
Downregulation of EGR1 mediates cisplatin-resistance through MIR152, at the transcriptional level
10
The transcription factor EGR1 promotes cell apoptosis under stress by regulating its downstream effectors including TP53/p53 (TRP53 in mice), TNF/TNF-α, RB1/Rb, and BAX. 17 Western blotting results showed that both A2780/CP70 and SKOV3/DDP cells exhibited very low levels of EGR1 protein expression compared with their parental control (Fig. 6A) . Interestingly, we found that the MIR152 gene promoter harbored candidate EGR1 DNA-binding consensus target sequences. To validate the direct interaction between EGR1 and the MIR152 gene, we performed an EMSA assay.
Incubation of the biotin-labeled DNA probe containing putative binding sites with nuclear protein fractions resulted in gel shift, which was completely inhibited by an excess of unlabeled DNA probe (Fig. 6B) . To further confirm that MIR152 is a transcriptional target of EGR1, we silenced EGR1 using specific EGR1 siRNA in A2780 cells, or overexpressed EGR1 in A2780/CP70 cells. As a result, MIR152 expression levels were about 2.5-fold lower in EGR1 knockdown cells, whereas 3.5-fold higher in EGR1-overexpressing cells (Fig. 6C, D) . EGR1 expression levels were also inversely correlated with ATG14 expression levels as genetic inhibition of EGR1 by siRNA caused the increase of ATG14 protein level (Fig. 6E) . To determine the role of EGR1 in cisplatin-resistance, we overexpressed EGR1 in A2780/CP70 cells, and then treated them with cisplatin, followed by a MTT assay. EGR1 overexpression significantly enhanced cisplatin-inhibited cell proliferation in cisplatin-resistant cells (Fig. 6F) . Taken together, EGR1 is an upstream regulator of the MIR152-ATG14 pathway, and is functional in cisplatin-resistance. (Fig. 6A) . The Welsh ovarian microarray reports a 3.9-fold lower EGR1 expression in ovarian carcinoma, whereas the Yoshihara ovarian microarray revealed a 12-fold reduction. 18, 19 ERCC1 is closely related with DNA repair and platinum resistance and is widely accepted as a biomarker for platinum resistance. 20 High ERCC1 expression represents strong DNA repair capacity, and thus leads to drug resistance and vice versa.
To explore the clinical implication of the proposed pathway, we utilized human ovarian tumors with ERCC1 scores defined by RT-PCR as described in the previous publication (Table 1) . 21 We analyzed EGR1 mRNA levels and MIR152 expression levels using quantitative real-time PCR, and found that both EGR1 and MIR152 expression levels were significantly higher in low ERCC1 tumors compared with high ERCC1 tumors, suggesting that EGR1 and MIR152 expression levels are positively correlated with potential cisplatin-sensitive tumors (Fig. 7B, C) . ATG14 expression levels were inversely correlated with MIR152 expression levels in ovarian tumors (Fig. 7D) . These results suggest that the EGR1/MIR152 pathway is associated with potential cisplatin-resistant ovarian cancer samples, thus validating the clinical relevance of our in vitro findings. Anti-autophagy strategies have been initiated in clinical trials that aim to overcome the development of resistance to radiation or chemotherapy treatments.
Discussion
Chloroquine, a commonly used autophagy inhibitor, has been used as a sensitizer in cancer therapies. 43 However, a controversy exists in terms of chloroquine efficacy. 44 One explanation is that normal cells also use autophagy to maintain homeostasis, and inhibition of autophagy by chloroquine would also sensitize healthy organs such as kidneys to chemotherapy resulting in severe side effects. 45 Given that basal levels of EGR1 and MIR152 are relatively high in normal cells, activation of the EGR1-MIR152 pathway may not affect signaling of normal cells, but will greatly increase the therapeutic response in cancer cells. Collectively, our data provide insights into novel mechanisms for acquired cisplatin-resistance. Activation of EGR1 and MIR152 may be a useful strategy to overcome ovarian cancer cell resistance by preventing cyto-protective autophagy.
Materials and Methods
Cell culture, establishment of stable cells, reagents, and antibodies
Ovarian cancer cells A2780 and cisplatin-resistant A2780/CP70 cells were cultured in 
RNA extraction and real-time quantitative PCR
Total RNAs were extracted using TRIzol (Invitrogen, 15596-018). The cDNA synthesis was performed using oligo(dT) 18 primers and M-MLV reverse transcriptase (Promega, 29473101). SYBR-Green RT-PCR was performed to detect EGR1, ATG14 and GAPDH mRNA levels using Power SYBR Green PCR Master Mix Kit (Applied Biosystems, 4309155). Quantitative real-time PCR primers for EGR1 and ATG14 were purchased from (Origene, HP205725, HP211256). Taqman RT-PCR was performed to detect miRNA expression levels using the Taqman miRNA reverse transcription kit (Applied Biosystem, 4366597) and the Taqman universal PCR master mix (Applied Biosystem, 4440038). A c c e p t e d M a n u s c r i p t
Flow cytometry analysis
Cells were transfected with the miRNA mimics or specific siRNAs followed by cisplatin treatment as indicated. ANXA5 and PI double-staining was performed using the Alexa 
EMSA assay
A2780 cellular nuclear extracts was prepared using a nuclear extraction kit (Cayman, 10009277). MIR152 DNA fragments (probe) in the promoter region containing EGR1
DNA-binding consensus sequences were amplified by PCR and followed by gel purification. Then the probe was labeled using a Biotin 3'end DNA labeling kit (Thermo Scientific, 89818). Binding reactions were performed using a Lightshift EMSA 
Statistical Analysis
Data are presented as mean ± SD from 3 independent experiments and analyzed by a 2-tailed Student t test and/or Pearson Correlation using SPSS 11.5 for Windows.
Differences were considered significant at a value of P ≤ 0.05. 
